Sector News

Abbott plunges deeper into diagnostics with $5.8bn Alere buy

February 2, 2016
Life sciences

Abbott is delving deeper into diagnostics with a definitive deal to buy test-maker Alere for around $5.8 billion.

Alere’s portfolio of products provides Abbott with access to new channels and geographies, including entry into fast-growing outlets, such as doctors’ offices, clinics, pharmacies and at-home testing, the firm noted.

The US drug giant said the move will see it become the leading diagnostics provider of point of care testing, with total diagnostics sales overshooting $7 billion after the transaction closes.

The move is expected to be immediately accretive to Abbott’s ongoing earnings per share upon close and significantly accretive thereafter, with around 12-13 cents added in 2017 and more than 20 cents in 2018. The combination is also expected to generate annual pre-tax synergies near $500 million by 2019 and increasing thereafter.

“The combination of Alere and Abbott will create the world’s premier point of care testing business and significantly strengthen and grow Abbott’s diagnostics presence,” said Miles White, Abott’s chairman and chief executive. “We want to offer our customers the best and broadest diagnostics solutions. Alere helps us do that.”

News of the deal comes shortly after Abbott posted a 15% drop in profit for the fourth quarter of the year, largely because of exchange rate effects.

By Selina McKee

Source: Pharma Times

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).